English
Tempus AI Stock: Winning the Business, Losing the Tape
Tempus AI stock trades near 52-week lows even after a Q1 beat-and-raise — 36% revenue growth, raised full-year guidance, an FDA clearance, and marquee pharma deals. The disconnect is the story. Buried under the sell-side's "Buy" ratings is a quiet concession: the analysts modeling Tempus no longer see profitability on the horizon. The growth is real; the path to making money on it just lost its date.
The bull headlines write themselves — AI precision medicine, 36% growth, blue-chip partners. So why does Tempus AI stock sit a few dollars off its 52-week low? Because the market is reading a page the press releases skip.
Why is Tempus AI stock near 52-week lows?
Despite the momentum, TEM trades around $46 — close to its 52-week low of $41.73 and roughly 55% below its $104.32 high, down about 29% over the past year. The cleanest tell came in early June: the stock jumped ~10% on June 4 on a stack of good news — FDA clearance for a tumor-only version of its xT CDx test, a deeper Bristol Myers Squibb collaboration, an Alzheimer's care-gap program — then handed all of it back the next session, falling ~11%. Good news, bad reaction. That is a market that has stopped paying up for the narrative.
Wasn't Q1 a strong quarter?
It was — on paper. Q1 revenue hit $348.1M, up 36.1%; diagnostics grew 34.7% with MRD test volume up roughly 500%; data and applications grew 40.5%. Adjusted EPS of -$0.13 beat the -$0.20 estimate, and management raised full-year guidance to about $1.59–1.60B with positive adjusted EBITDA. But the GAAP net loss was still $125.9M, and the company is funding growth with a $400M zero-coupon convertible — future dilution by another name. Beat-and-raise on the top line; still bleeding at the bottom.
What does the "Buy" rating actually hide?
Here's the contradiction the consensus glosses over. The Street keeps a Buy-leaning average rating and a ~$66 price target — roughly 44% above the current price. Yet the same analysts have quietly pushed breakeven beyond the foreseeable future; models that once penciled in a modest 2028 profit no longer do, and targets are sliding ($72.40 → $67.20). You're being sold a "scale-into-profitability" thesis by the very people who just deleted the profitability date.
What's the non-consensus takeaway?
Be fair: the moat is real — over 500 petabytes of multimodal clinico-genomic data, brand-name pharma partners, and a genuine lead in AI-driven diagnostics. Tempus is not a story with no business underneath it. But the bull case has always rested on one bridge: growth now, profits later. With insiders net sellers, a reported ~20% of the float sold short, and the analysts' own profitability horizon receding, a stock near 52-week lows isn't acting irrationally. It's repricing a growth-forever story that quietly lost its endgame.
FAQ
Is Tempus AI profitable? No. Q1 2026 GAAP net loss was $125.9M; adjusted EPS was -$0.13 (a beat). Analysts no longer model breakeven within the foreseeable future.
How fast is Tempus growing? Q1 revenue rose 36.1% to $348.1M; full-year guidance is about $1.59–1.60B (~25% growth).
When does Tempus report next? Q2 2026 results are expected around early August 2026.
Forward look: The next real test is early August: whether the high-margin data business scales fast enough to make the profitability question answerable again — or whether the burn-plus-dilution storyline hardens.
Bonus rebate to help investors grow in the trading world!
